Adjusted bivariate analysis
| . | PFS . | OS . |
|---|---|---|
| Unadjusted VEN combo (vs mono) | HR, 1.0; CI, 0.6-1.8; P = .7 | HR, 1.2; CI, 0.6-2.3; P = .5 |
| VEN combo (vs mono) + number prior therapies | HR, 1.0; CI, 0.6-1.7; P = .9 | HR, 1.2; CI, 0.6-2.2; P = .5 |
| VEN combo (vs mono) + del17p | HR, 1.0; CI, 0.6-1.8; P = .12 | HR, 1.3; CI, 0.7-2.7; P = .4 |
| VEN combo (vs mono) + del11p | HR, 1.4; CI, 0.5-1.5; P = .3 | HR, 1.2; CI, 0.5-2.7; P = .4 |
| VEN combo (vs mono) + complex karyotype | HR, 1.0; CI, 0.5-2.1; P = .9 | HR, 1.1; CI, 0.4-2.6; P = .18 |
| VEN combo (vs mono) + IGHV unmutated | HR, 1.1; CI, 0.5-2.3; P = .8 | HR, 1.0; CI, 0.4-2.5; P = .9 |
| VEN combo (vs mono) + prior ibrutinib | HR, 0.9; CI, 0.5-1.8; P = .9 | HR, 1.1; CI, 0.6-2.2; P = .8 |
| VEN combo (vs mono) + prior chemoimmunotherapy | HR, 1.2; CI, 0.6-2.4; P = .7 | HR, 1.1; CI, 0.5-2.4; P = .8 |
| . | PFS . | OS . |
|---|---|---|
| Unadjusted VEN combo (vs mono) | HR, 1.0; CI, 0.6-1.8; P = .7 | HR, 1.2; CI, 0.6-2.3; P = .5 |
| VEN combo (vs mono) + number prior therapies | HR, 1.0; CI, 0.6-1.7; P = .9 | HR, 1.2; CI, 0.6-2.2; P = .5 |
| VEN combo (vs mono) + del17p | HR, 1.0; CI, 0.6-1.8; P = .12 | HR, 1.3; CI, 0.7-2.7; P = .4 |
| VEN combo (vs mono) + del11p | HR, 1.4; CI, 0.5-1.5; P = .3 | HR, 1.2; CI, 0.5-2.7; P = .4 |
| VEN combo (vs mono) + complex karyotype | HR, 1.0; CI, 0.5-2.1; P = .9 | HR, 1.1; CI, 0.4-2.6; P = .18 |
| VEN combo (vs mono) + IGHV unmutated | HR, 1.1; CI, 0.5-2.3; P = .8 | HR, 1.0; CI, 0.4-2.5; P = .9 |
| VEN combo (vs mono) + prior ibrutinib | HR, 0.9; CI, 0.5-1.8; P = .9 | HR, 1.1; CI, 0.6-2.2; P = .8 |
| VEN combo (vs mono) + prior chemoimmunotherapy | HR, 1.2; CI, 0.6-2.4; P = .7 | HR, 1.1; CI, 0.5-2.4; P = .8 |